90 related articles for article (PubMed ID: 22169317)
1. [Research update on PD-1/PD-L1 pathway in hematological diseases].
Li Y; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1523-7. PubMed ID: 22169317
[TBL] [Abstract][Full Text] [Related]
2. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
3. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
Zatloukalová P; Pjechová M; Babčanová S; Hupp TR; Vojtěšek B
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):72-77. PubMed ID: 27846724
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
5. Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis.
Liu Q; Li CS
Chin Med J (Engl); 2017 Apr; 130(8):986-992. PubMed ID: 28397730
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
Choi DC; Tremblay D; Iancu-Rubin C; Mascarenhas J
Ann Hematol; 2017 Jun; 96(6):919-927. PubMed ID: 28062906
[TBL] [Abstract][Full Text] [Related]
7. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.
Zandberg DP; Strome SE
Oral Oncol; 2014 Jul; 50(7):627-32. PubMed ID: 24819861
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
9. Recent Insight into the Role of the PD-1/PD-L1 Pathway in Feto-Maternal Tolerance and Pregnancy.
Zhang YH; Tian M; Tang MX; Liu ZZ; Liao AH
Am J Reprod Immunol; 2015 Sep; 74(3):201-8. PubMed ID: 25640631
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
Ji M; Liu Y; Li Q; Li XD; Zhao WQ; Zhang H; Zhang X; Jiang JT; Wu CP
J Transl Med; 2015 Jan; 13():5. PubMed ID: 25592115
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.
Xiao W; Jiang LF; Deng XZ; Zhu DY; Pei JP; Xu ML; Li BJ; Wang CJ; Zhang JH; Zhang Q; Zhou ZX; Ding WL; Xu XD; Yue M
Immunol Res; 2016 Apr; 64(2):412-23. PubMed ID: 26286967
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
15. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
18. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
19. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
20. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
